Rhythm Pharmaceuticals Announces Two Publications Detailing Burden Of Hyperphagia And Obesity On Patients And Caregivers Living With Bardet-Biedl Syndrome
Portfolio Pulse from Benzinga Newsdesk
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) has announced two new publications detailing the burden of hyperphagia and obesity on patients and caregivers living with Bardet-Biedl Syndrome (BBS). The research is based on results of The CAREgiver Burden in BBS (CARE-BBS) study and is published in The Orphanet Journal of Rare Diseases.
July 19, 2023 | 12:16 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Rhythm Pharmaceuticals has published new research on the burden of hyperphagia and obesity on patients and caregivers living with Bardet-Biedl Syndrome.
The publication of new research by Rhythm Pharmaceuticals could potentially increase its reputation in the biopharmaceutical industry. However, it's unclear how this will directly impact the company's stock price in the short term, hence the neutral score.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 100